FITC-Linked Polyclonal Antibody to Peroxiredoxin 1 (PRDX1)
| Code | Size | Price |
|---|
| LAC749Hu81-200ul | 200ul | £293.00 |
Quantity:
| LAC749Hu81-1ml | 1ml | £686.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Documents
Further Information
Alternative Names:
MSP23; NKEFA; PAG; PAGA; PAGB; TDPX2; Natural killer cell-enhancing factor A; Proliferation-associated; Thioredoxin peroxidase 2; Thioredoxin-dependent peroxide reductase 2
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Peroxiredoxin 1
Reactivity:
Mu;Ra;
Source:
Antibody labeling
Usage:
Western blotting: 0.2-2ug/mL;1:250-2500
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
References
https://www.researchgate.net/profile/Balint-Alasztics/publication/268792401_The_role_of_angiogenic_factors_in_preeclampsia/links/63b17dffa03100368a45c0e7/The-role-of-angiogenic-factors-in-preeclampsia.pdf;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Peroxiredoxin 1 (PRDX1) | RPC749Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||